Join Growin Stock Community!

Integra lifesciences holdings corporationIART.US Overview

US StockHealthcare
(No presentation for IART)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IART AI Insights

IART Overall Performance

IART AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IART Recent Performance

-6.15%

Integra lifesciences holdings corporation

0.05%

Avg of Sector

-0.31%

S&P500

IART PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IART Key Information

IART Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IART Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Price of IART

IART FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IART Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.63
PE Ratio (TTM)
-
Forward PE
3.80
PS Ratio (TTM)
0.54
PB Ratio
0.85
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
50.86%
Net Margin
-31.58%
Revenue Growth (YoY)
1.53%
Profit Growth (YoY)
-5.72%
3-Year Revenue Growth
3.00%
3-Year Profit Growth
-4.06%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.63
PE Ratio (TTM)
-
Forward PE
3.80
PS Ratio (TTM)
0.54
PB Ratio
0.85
Price-to-FCF
-
Gross Margin
50.86%
Net Margin
-31.58%
Revenue Growth (YoY)
1.53%
Profit Growth (YoY)
-5.72%
3-Year Revenue Growth
3.00%
3-Year Profit Growth
-4.06%

  • When is IART's latest earnings report released?

    The most recent financial report for Integra lifesciences holdings corporation (IART) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IART's short-term business performance and financial health. For the latest updates on IART's earnings releases, visit this page regularly.

  • What is the operating profit of IART?

    According to the latest financial report, Integra lifesciences holdings corporation (IART) reported an Operating Profit of 23.04M with an Operating Margin of 5.3% this period, representing a decline of 35.33% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is IART's revenue growth?

    In the latest financial report, Integra lifesciences holdings corporation (IART) announced revenue of 434.93M, with a Year-Over-Year growth rate of -1.74%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does IART have?

    As of the end of the reporting period, Integra lifesciences holdings corporation (IART) had total debt of 2.03B, with a debt ratio of 0.56. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does IART have?

    At the end of the period, Integra lifesciences holdings corporation (IART) held Total Cash and Cash Equivalents of 235.05M, accounting for 0.07 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does IART go with three margins increasing?

    In the latest report, Integra lifesciences holdings corporation (IART) did not achieve the “three margins increasing” benchmark, with a gross margin of 50.8%%, operating margin of 5.3%%, and net margin of -0.4%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess IART's profit trajectory and future growth potential.

  • Is IART's EPS continuing to grow?

    According to the past four quarterly reports, Integra lifesciences holdings corporation (IART)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.02. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IART?

    Integra lifesciences holdings corporation (IART)'s Free Cash Flow (FCF) for the period is -5.4M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 125.53% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of IART?

    The latest valuation data shows Integra lifesciences holdings corporation (IART) has a Price-To-Earnings (PE) ratio of -1.71 and a Price/Earnings-To-Growth (PEG) ratio of 2.05. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.